<DOC>
	<DOCNO>NCT02231632</DOCNO>
	<brief_summary>The purpose Phase 2/3 trial ass safety immunogenicity Live attenuate Poliomyelitis vaccine ( human diploid cell )</brief_summary>
	<brief_title>The Immunogenicity Safety Live Attenuated Poliomyelitis Vaccine ( Human Diploid Cell )</brief_title>
	<detailed_description>Live attenuate Poliomyelitis vaccine ( human diploid cell ) use poliovirus prevention child 2 year old , Which develop Institute Medical Biology , Chinese Academy Medical Sciences , base two product : Poliomyelitis Vaccine Dragee Candy ( Monkey Kidney Cell ) , Live ; Poliomyelitis（Live）Vaccine ( Monkey Kidney Cell ) , Oral . After safety prove phase 1 clinical trail evaluation , phase 2/3 trail start Guangxi Province , China 2011-2012 . The purpose trial ass safety immunogenicity healthy child 2,3 4 month old .</detailed_description>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Only subject fulfil follow criterion eligible study : People age 2 month 4 month old . The subject subject ' guardian able understand sign inform consent The subject subject ' guardian allow comply requirement protocol Subjects temperature &lt; =37.0°C axillary set The subject sign informed consent already The subject never vaccinate Poliomyelitis Vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>efficacy</keyword>
</DOC>